Brian J. Druker, MD
Oregon Health & Science University Cancer Institute
Howard Hughes Medical Institute
Dr. Druker helped transform cancer treatment through research that led to the development of imatinib (Gleevec®), a drug that successfully targets and attacks the genetic defect underlying chronic myeloid leukemia (CML). Today, the average 5-year survival for CML patients who are treated with imatinib is close to 90%. Dr. Druker's current research focuses on why a small percentage of newly diagnosed CML patients develop resistance to imatinib and why traces of leukemia remain in a patient’s body even after treatment ends.
Imatinib (Gleevec) as a Paradigm ofTargeted Cancer Therapies
Brian J. Druker, MD, and Cancer Center Director Michelle Le Beau, PhD